NVO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	4.82M
Average Volume	5.06M
Market Cap	547.04B
EPS	$0 ( 2024-01-31 )
Next earnings date	( $0.770 ) 2024-05-02
Last Dividend	$0.884 ( 2023-08-18 )
Next Dividend	$0 ( N/A )
P/E	46.31
ATR14	$0.0760 (0.06%)

Volume Correlation

Long: -0.45 (neutral)

Short: -0.84 (strong negative)

Signal:(58.52) Neutral

Novo Nordisk A/S Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novo Nordisk A/S Correlation - Currency/Commodity

0.62
( weak )

0.58
( weak )

0.00
( neutral )

0.58
( weak )

0.67
( moderate )

-0.36
( neutral )

Novo Nordisk A/S Financials

Annual	2023
Revenue:	$232.26B
Gross Profit:	$196.50B (84.60 %)
EPS:	$18.67

Q4	2023
Revenue:	$65.86B
Gross Profit:	$55.85B (84.80 %)
EPS:	$4.92

Q3	2023
Revenue:	$58.73B
Gross Profit:	$49.02B (83.46 %)
EPS:	$5.02

Q2	2023
Revenue:	$54.30B
Gross Profit:	$46.44B (85.53 %)
EPS:	$4.33

Financial Reports:

No articles found.

Novo Nordisk A/S Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.584 (N/A)	$0 (N/A)	$1.189 (N/A)	$0 (N/A)	$0.884 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Novo Nordisk A/S Dividend Information - Dividend Knight

Dividend Sustainability Score: 7.78 - good (77.78%) | Divividend Growth Potential Score: 4.41 - Stable (11.80%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.000600	1982-04-23
Last Dividend	$0.884	2023-08-18
Next Dividend	$0	N/A
Payout Date	2023-08-29
Next Payout Date	N/A
# dividends	53	--
Total Paid Out	$15.84	--
Avg. Dividend % Per Year	2.26%	--
Score	4.26	--
Div. Sustainability Score	7.78
Div.Growth Potential Score	4.41
Div. Directional Score	6.09	--

Next Divdend (Est)
(2024-05-27)

$0.906 Estimate 6.52 %

Dividend Stability

0.26 Very Poor

Dividend Score

4.26

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1982	$0.000600	0.30%
1983	$0.00274	1.29%
1984	$0.00288	1.02%
1985	$0.00259	2.18%
1986	$0.00344	2.37%
1987	$0.00414	2.50%
1988	$0.00522	4.51%
1989	$0.00463	2.39%
1990	$0.00624	2.51%
1991	$0.00509	1.64%
1992	$0.00600	1.32%
1993	$0.00540	1.22%
1994	$0.0112	2.26%
1995	$0.00840	1.80%
1996	$0.0158	2.26%
1997	$0.0112	1.24%
1998	$0.0161	1.13%
1999	$0.0164	1.17%
2000	$0.0422	3.13%
2001	$0.0318	1.79%
2002	$0.0369	1.84%
2003	$0.0523	3.56%
2004	$0.0745	3.62%
2005	$0.0840	3.17%
2006	$0.0966	3.39%
2007	$0.122	2.93%
2008	$0.177	2.77%
2009	$0.207	3.92%
2010	$0.281	4.28%
2011	$0.364	3.27%
2012	$0.499	4.26%
2013	$0.637	3.84%
2014	$0.830	4.52%
2015	$0.760	3.58%
2016	$1.411	4.92%
2017	$1.137	6.33%
2018	$1.137	4.20%
2019	$1.238	5.29%
2020	$1.301	4.46%
2021	$1.506	4.22%
2022	$1.620	2.98%
2023	$2.07	3.03%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PVL	Dividend Royal	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
MTR	Dividend Royal	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.360	1.500	2.79	4.19	[0 - 0.5]
returnOnAssetsTTM	0.266	1.200	1.130	1.356	[0 - 0.3]
returnOnEquityTTM	0.905	1.500	1.056	1.585	[0.1 - 1]
payoutRatioTTM	0.380	-1.000	6.20	-6.20	[0 - 1]
currentRatioTTM	0.823	0.800	-0.884	-0.708	[1 - 3]
quickRatioTTM	0.622	0.800	-1.048	-0.839	[0.8 - 2.5]
cashRatioTTM	0.0848	1.500	-0.640	-0.960	[0.2 - 2]
debtRatioTTM	0.0859	-1.500	8.57	-10.00	[0 - 0.6]
interestCoverageTTM	69.78	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	24.39	2.00	1.869	3.74	[0 - 30]
freeCashFlowPerShareTTM	15.68	2.00	2.16	4.32	[0 - 20]
debtEquityRatioTTM	0.253	-1.500	8.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.846	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.442	1.000	3.17	3.17	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.03	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.739	0.800	8.41	6.73	[0.5 - 2]
Total Score				7.78

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	46.26	1.000	5.43	0	[1 - 100]
returnOnEquityTTM	0.905	2.50	4.25	1.585	[0.1 - 1.5]
freeCashFlowPerShareTTM	15.68	2.00	4.77	4.32	[0 - 30]
dividendYielPercentageTTM	0.209	1.500	4.77	0	[0 - 0.4]
operatingCashFlowPerShareTTM	24.39	2.00	1.869	3.74	[0 - 30]
payoutRatioTTM	0.380	1.500	6.20	-6.20	[0 - 1]
pegRatioTTM	0.315	1.500	-1.236	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.469	1.000	0.777	0	[0.1 - 0.5]
Total Score				4.41

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.